Compare CETX & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CETX | GOVX |
|---|---|---|
| Founded | 1998 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6M | 3.8M |
| IPO Year | 2016 | 1996 |
| Metric | CETX | GOVX |
|---|---|---|
| Price | $2.44 | $0.46 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 21.0K | ★ 668.0K |
| Earning Date | 05-12-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $120,628,200.00 | $2,489,145.00 |
| Revenue This Year | $20.41 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 28.73 | N/A |
| 52 Week Low | $0.37 | $0.12 |
| 52 Week High | $9.70 | $4.40 |
| Indicator | CETX | GOVX |
|---|---|---|
| Relative Strength Index (RSI) | 39.59 | 29.17 |
| Support Level | $2.43 | $0.14 |
| Resistance Level | $3.21 | $0.86 |
| Average True Range (ATR) | 0.12 | 0.07 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 21.51 | 3.65 |
Cemtrex Inc is a multi-industry technology company. It has expanded into a range of sectors, including smart technologies, virtual and augmented realities, industrial solutions, and intelligent security systems. The company's operating segment includes the Security segment and the Industrial Services segment. The security segment provides end-to-end security to all industrial, corporate, and governmental security via its owned subsidiary, Vicon. Whereas the AIS part Industrial Service Segment is expertise services for rigging, millwrighting, in-plant maintenance, equipment erection, relocation, and disassembly to diversified customers. It generates maximum revenue from the Industrial Service Segment, and from the USA. It also operates UK, USA, and Other.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.